Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lanlan Yu

Showing results (111-120 of 113) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 113 results.
Scientific Reports|January 31, 2025
Safety and efficacy of oral administrated cepharanthine in non-hospitalized, asymptomatic or mild COVID-19 patients: a Double-blind, randomized, placebo-controlled trial : Author detialsJianyi Wei, Shupeng Liu, Yuexiang Bian, et al.
Leukemia|January 10, 2022
A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myelomaSatoko Kakiuchi-Kiyota, Thorsten Ross, Heidi Ackerly Wallweber, et al.
Journal of Medicinal Chemistry|March 3, 2024
Discovery of TRPA1 Antagonist <b>GDC-6599</b>: Derisking Preclinical Toxicity and Aldehyde Oxidase Metabolism with a Potential First-in-Class Therapy for Respiratory DiseaseJack A Terrett, Justin Q Ly, Paula Katavolos, et al.
Pageof 12

Showing results (111-120 of 113) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 113 results.
Scientific Reports|January 31, 2025
Safety and efficacy of oral administrated cepharanthine in non-hospitalized, asymptomatic or mild COVID-19 patients: a Double-blind, randomized, placebo-controlled trial : Author detialsJianyi Wei, Shupeng Liu, Yuexiang Bian, et al.
Leukemia|January 10, 2022
A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myelomaSatoko Kakiuchi-Kiyota, Thorsten Ross, Heidi Ackerly Wallweber, et al.
Journal of Medicinal Chemistry|March 3, 2024
Discovery of TRPA1 Antagonist <b>GDC-6599</b>: Derisking Preclinical Toxicity and Aldehyde Oxidase Metabolism with a Potential First-in-Class Therapy for Respiratory DiseaseJack A Terrett, Justin Q Ly, Paula Katavolos, et al.
Pageof 12